ARV-471 (vepdegestrant) is an investigational oral PROTAC estrogen receptor degrader being developed by Arvinas and Pfizer for ER-positive, HER2-negative breast cancer. The program has advanced through phase III testing and has regulatory submissions in progress. It is not yet an approved marketed therapy.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
Proteolysis-targeting chimeras (PROTACs) are advancing from experimental to clinical-stage cancer therapies, with first candidates entering Phase III trials. The technology degrades target proteins rather than blocking them, offering new options for previously undruggable targets.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05732428 |
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China |
COMPLETED | PHASE1 |
| NCT05673889 |
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults |
COMPLETED | PHASE1 |
| NCT05654623 |
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05652660 |
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults |
COMPLETED | PHASE1 |
| NCT05573555 |
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05549505 |
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery |
COMPLETED | PHASE2 |
| NCT05548127 |
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT04072952 |
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer |
COMPLETED | PHASE1/PHASE2 |
| NCT01042379 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
RECRUITING | PHASE2 |
